Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu

Yongli Zheng, Hong Xu, Ming Yang, Yilan Zeng, Hong Chen, Ru Liu, Qingfeng Li, Na Zhang, Dan Wang

Chengdu Public Health Clinical Medical Center & Public Health Clinical Center of Chengdu University of Traditional Chinese Medicine, Chengdu, China

Chengdu Sixth People’s Hospital, China

ARTICLE INFO

Keywords:
- Epidemiological characteristics
- Clinical features
- Critical illness
- COVID-19
- Chengdu

ABSTRACT

Background: In December 2019, Wuhan, China, experienced an outbreak of coronavirus (COVID-19). The number of cases has increased rapidly, but information on the clinical characteristics remains limited. Objectives: This paper describes the epidemiological and clinical characteristics of COVID-19. Early detection and identification of critically ill patients is necessary to facilitate scientific classification and treatment. Study design: This study included a retrospective, single-center case series of 99 consecutively hospitalized patients with confirmed COVID-19 at Chengdu Public Health Clinical Medical Center in Chengdu, China, from January 16 to February 20, 2020. The final date of follow-up was February 23, 2020.

We collected and analyzed epidemiological, demographic, clinical, laboratory, radiological, and treatment data. We compared outcomes of critically ill patients and noncritically ill patients.

Results: Of the 99 hospitalized patients with COVID-19, the median age was 49 years (minimum, 3 months; maximum, 87 years) and 51 (52 %) were men; 42 (42 %) had traveled to or lived in Wuhan and 48 (49 %) had come into close contact with patients with new coronavirus pneumonia; 41 (41 %) patients had underlying disease. Common symptoms included fever (85 [86 %]), dry cough (84 [85 %]), and fatigue (72 [73 %]). We analyzed the clinical characteristics of patients. We expressed the measurement data as mean ± standard deviation. We collected data for age (49.39 ± 18.45 years), number of hospital days (12.32 ± 6.70 days), and laboratory indicators.

We compared critically ill and noncritically ill patients: p-values for age, C-reactive protein, high-sensitivity troponin T, prothrombin time, fibrin degradation products, D-Dimer, and CD4+ count were p < 0.001; and p-values for hospital days, white blood cell, neutrophil, lymphocyte, creatine kinase isoenzyme, myoglobin, N-terminal brain natriuretic peptide, and CD8+ count were p < 0.05.

Conclusions: We collected data from a single-center case series of 32 hospitalized patients who were critically ill with confirmed COVID-19 in Chengdu, China, and compared data with 67 noncritically ill patients. Elderly patients had chronic underlying diseases, notably cardiovascular disease. Higher C-reactive protein levels, higher levels of myocardial damage, and higher brain natriuretic peptide levels; lower white blood cells, neutrophils, and lymphocytes; and lower CD4 and CD8 counts could be used for early detection and identification of critically ill patients, and dynamic Data observation was more important than at a single moment.

1. Background

Since the end of December 2019, a new type of coronavirus pneumonia appeared in Wuhan City. The World Health Organization named this new coronavirus pneumonia COVID-19 [1]. This virus spread to other parts of the country as well as to other countries and regions around the world.

The number of patients has increased rapidly, but information on the clinical characteristics of these critically ill patients remains limited. Case data on COVID-19 from other cities is even more scarce than in Wuhan.

2. Objectives

In the face of emerging outbreaks of infectious diseases, it is extremely important to fully understand the spread, epidemiology,
clinical characteristics, progression, and prognosis of the disease. By identifying the clinical characteristics of critical cases, we can detect and identify critically ill patients earlier. Early identification and prediction of critical illness is critical to ensure early and immediate focus on the most critically ill cases, reasonable allocation of time, and use of high-quality resources.

3. Study design

We collected data for a total of 99 COVID-19 cases from Chengdu Public Health Clinical Medical Center from January 16, 2020, to February 20, 2020. According to disease development and condition, we divided the cases into two groups: critically ill patients and noncritically ill patients. We separated the noncritically ill patients and the critically ill patients in the general ward and in the intensive care unit (ICU) equipped with negative pressure.

We performed a retrospective study on the 99 patients and collected clinical data, including general information, epidemiological history, medical history, symptoms, signs, imaging examinations, and laboratory examinations. We summarized the epidemiological characteristics and clinical characteristics of patients, evaluated chest imaging characteristics, and examined prognosis of disease progression.

Diagnostic criteria met the guidelines for diagnosis and treatment of COVID-19 (trial version 5) [2]. We confirmed all cases according to nucleic acid real-time-polymerase chain reaction (RT-PCR) tests. Most of the patients had lived in Wuhan or came into close contact with patients who had COVID-19.

Critical cases met any of the following criteria: (1) Increased breathing rate (> 30 beats/min), difficulty breathing or cyanosis of the lips; (2) upon inhalation, oxygen saturation was ≤ 93 %; (3) arterial blood oxygen partial pressure (PaO2)/oxygen concentration (FiO2) was ≤ 300 mmHg (1 mmHg = 0.133 kPa); (4) pulmonary imaging showed multilobular lesions or lesion progression within 50 h of > 50 %; or (5) other clinical conditions requiring hospitalization. Severe critical cases met one of the following conditions: (1) respiratory failure occurred, requiring mechanical ventilation; (2) shock occurred; or (3) ICU monitoring and treatment were required for combined organ failure.

We processed data using SPSS 20.0 statistical software. We expressed measurement data as mean ± standard deviation (x ± s), and used an t-test. We expressed count data as rate (%), and used a χ2 test. P-values < 0.05 indicated that the difference was statistically significant.

4. Results

Of the 99 patients with COVID-19, 42 patients (42 %) traveled to or lived in Wuhan and 48 patients (49 %) had come into close contact with patients who had COVID-19. An additional nine cases (9 %) had no clear epidemiological history. We detected and confirmed 19 male and 13 female critically ill patients. There was no significant difference in the sex of noncritically ill patients (see Table 2). We calculated the mean and standard deviation of the measurement data for these two groups, and compared whether these indicators were statistically different between the two groups according to the p-value.

5. Discussion

We asked all patients for details about their epidemiological history. We identified that 42 patients lived in or had been to Wuhan, and 49 patients had close contact with patients with confirmed COVID-19. The other eight cases had no clear epidemiological history. We found no statistical difference (χ2, 0.184, > 0.05) in the epidemiological history of critically ill patients and noncritically ill patients. The patients admitted in the early stage had a history of touring or living in Wuhan (first-generation patients), and the patients admitted in the later stage usually had close contact with patients with confirmed COVID-19 (second-generation patients). The first generation of patients was highly distributed and related to contacts in Wuhan, but the second generation of patients showed a high degree of family clustering [3]. This may indicate that respiratory droplets and close contact are the primary routes of transmission. This finding also showed that benefits of reducing the flow of people and large gatherings as well as staying at home and self-isolation have begun to take effect on reducing transmission [4].

The study included 48 female patients and 51 male patients, including 19 male and 13 female critically ill patients. There was no statistically significant difference between the two groups (p-value 0.293 > 0.05).

The mean age of critically ill patients was 63.8 years, whereas that of noncritically ill patients was 42.5 years [5]. This difference (p-value 0.000 < 0.001) was extremely significant and statistically significant. With an increase in age, the probability of occurrence of basic diseases also increased significantly. Of all patients, 41 cases had significant chronic disease. Among the critically ill patients, 17 cases had heart-related disease, 3 cases had type 2 diabetes, and 1

| Table 1 | Clinical characteristics of 99 patients at admission. |
|---------|-----------------------------------------------------|
| AGE (years) | 99 | 0.25 | 87.00 | 49.40 | 18.45 |
| HOSPITAL DAY (day) | 99 | 5.00 | 50.00 | 23.82 | 11.18 |
| WBC (10^9/l) | 99 | 2.29 | 15.44 | 6.21 | 2.64 |
| NEU (10^9/l) | 99 | 1.21 | 14.49 | 4.31 | 2.46 |
| LYM (10^9/l) | 99 | 0.22 | 8.60 | 1.81 | 1.26 |
| CRP (mg/l) | 99 | 0.80 | 174.17 | 24.79 | 35.49 |
| ALT (u/l) | 92 | 7.00 | 208.00 | 35.16 | 36.09 |
| AST (u/l) | 92 | 7.00 | 502.00 | 34.59 | 52.44 |
| CKMB (ng/mL) | 96 | .30 | 42.00 | 5.42 | 6.57 |
| MYO (ng/mL) | 88 | 21.00 | 1299.00 | 53.10 | 139.19 |
| TNIHSSST (pg/mL) | 88 | 3.00 | 1742.00 | 430.72 | 1965.34 |
| NT-proBNP (pg/mL) | 84 | 5.00 | 17324.00 | 430.72 | 1965.34 |
| PT (s) | 94 | 11.50 | 17.40 | 13.10 | .80 |
| FDP (mg/l) | 94 | 1.40 | 35.50 | 4.03 | 5.53 |
| D-Dimer (mg/l) | 94 | .23 | 17.70 | 1.41 | 2.51 |
| CD4 (cells/ul) | 89 | 38.00 | 2699.00 | 471.65 | 355.85 |
| CD8 (cells/ul) | 89 | 35.00 | 1422.00 | 306.24 | 238.28 |

Note: WBC, white blood cells; NEU, neutrophil; LYM, lymphocyte; CRP, C-reactive protein; CKMB, creatine kinase isoenzyme; MYO, myoglobin; TNIHSSST, high-sensitivity troponin T; NT-proBNP, N-terminal brain natriuretic peptide; PT, prothrombin time; FDP, fibrin degradation products; CD4, CD4 + count; CD8, CD8 + count.
Table 2
Comparison of laboratory indicators between critically ill and noncritically ill patients.

| CONDITION     | N   | MEAN  | SD   | p-value |
|---------------|-----|-------|------|---------|
| AGE           |     |       |      |         |
| Critical      | 32  | 63.81 | 16.51| 0.000   |
| Noncritical   | 67  | 42.51 | 15.11|         |
| HOSPITAL DAY  |     |       |      |         |
| Critical      | 32  | 35.97 | 8.99 | 0.000   |
| Noncritical   | 67  | 18.02 | 6.48 |         |
| WBC*          |     |       |      |         |
| Critical      | 32  | 7.00  | 3.09 |         |
| Noncritical   | 67  | 5.83  | 2.33 | 0.040   |
| NEU*          |     |       |      |         |
| Critical      | 32  | 5.42  | 2.84 |         |
| Noncritical   | 67  | 3.78  | 2.08 | 0.002   |
| LYM*          |     |       |      |         |
| Critical      | 32  | 2.19  | 1.44 |         |
| Noncritical   | 67  | 1.64  | 1.12 | 0.039   |
| CRP*          |     |       |      |         |
| Critical      | 32  | 49.63 | 48.11|         |
| Noncritical   | 67  | 12.93 | 18.48| 0.000   |
| ALT*          |     |       |      |         |
| Critical      | 30  | 42.37 | 48.88|         |
| Noncritical   | 62  | 31.68 | 27.75| 0.184   |
| AST*          |     |       |      |         |
| Critical      | 30  | 51.23 | 88.67|         |
| Noncritical   | 62  | 26.53 | 12.73| 0.033   |
| CKMB*         |     |       |      |         |
| Critical      | 31  | 3.55  | 5.34 |         |
| Noncritical   | 65  | 6.32  | 6.94 | 0.053   |
| MYO*          |     |       |      |         |
| Critical      | 31  | 97.50 | 229.10|        |
| Noncritical   | 57  | 28.96 | 17.22| 0.026   |
| TNTHSST*      |     |       |      |         |
| Critical      | 31  | 24.80 | 37.77|         |
| Noncritical   | 57  | 5.47  | 2.58 | 0.000   |
| NT-proBNP*    |     |       |      |         |
| Critical      | 54  | 1085.55| 3217.11|        |
| Noncritical   | 62  | 66.92 | 90.85| 0.022   |
| PT*           |     |       |      |         |
| Critical      | 32  | 13.49 | 9.6  |         |
| Noncritical   | 62  | 12.91 | 63   | 0.001   |
| FDP*          |     |       |      |         |
| Critical      | 32  | 6.72  | 8.36 |         |
| Noncritical   | 62  | 2.65  | 2.33 | 0.001   |
| D-Dimer       |     |       |      |         |
| Critical      | 32  | 2.65  | 3.93 |         |
| Noncritical   | 62  | .78   | .76  | 0.000   |
| CD4*          |     |       |      |         |
| Critical      | 26  | 273.92| 185.21|        |
| Noncritical   | 65  | 553.25| 377.81| 0.001   |
| CD8*          |     |       |      |         |
| Critical      | 26  | 202.31| 144.31|        |
| Noncritical   | 63  | 349.13| 256.50|        |

In critically ill patients who had worsening of the disease, we observed progressively decreased blood leukocytes, neutrophils, lymphocytes, CD4, and CD8, and increased myocardial damage, cardiac function indexes, and coagulation indexes. In cases of the virus that were detected early, we observed relatively less damage to the liver and kidneys [9]. The death cases progressed rapidly to acute respiratory distress syndrome, septic shock, difficult-to-correct metabolic acidosis, and coagulopathy and multiple organ failure. In general, the severity of disease for most patients could be determined according to these clinical characteristics 1 week after admission, and patients could be identified as improving or dying 2–3 weeks after admission [10]. C-reactive protein > 49.6 mg/L, MYO > 97.5 ng/mL, TNTHSST > 24.8 pg/mL, NT-proBNP > 1085.5 pg/mL, PT > 14.5 s, FDP > 6.7 ug/mL, D-Dimer > 2.6 ug/mL, CD4 < 274 cells/ul, and CD8 < 202 cells/ul were relatively dangerous and demonstrated a manifestation of critical illness. This finding was similar to cases reported from the hospital in Wuhan [11].

5 The average length of hospital stay for all patients was 24 days, with a minimum of 5days and a maximum of 50 days. The average length of hospital stay for critically ill patients was 36 days, and for noncritically ill patients was 18 days. We identified significant statistical differences between the two groups (p-value 0.000, < 0.001).

6 This retrospective study has some obvious shortcomings. For example, in many laboratory inspections, we could not completely collect data according to the admission stage. At these stages, such as when the patient was newly admitted, when the condition changed, when the patient improved, or when they died, we could distinguish the progress of each patient's condition. Therefore, some indicators lacked a certain degree of comparability. In addition, although this was a retrospective study, because of large differences in enrollment time, some patients have not yet been discharged, and their outcome and prognosis will still change.

In summary, we collected data on cases of critically ill patients of COVID-19 and compared them with noncritically ill patients. We found that the elderly exhibited chronic underlying diseases, especially cardiovascular disease, higher C-reactive protein levels, and higher myocardium. Damage levels; higher brain natriuretic peptide levels; lower white blood cells, neutrophils, and lymphocytes; and lower CD4 and CD8 counts could enable early detection and identification of critically ill patients. Dynamic observation was important and facilitated concentration of superior resources to improve patient prognosis [12]. Although there were 32 critically ill patients, we immediately transferred them to the ICU to ensure a good prognosis for the most critically ill patients.

CRediT authorship contribution statement

Yongli Zheng: Conceptualization, Writing - review & editing, Writing - original draft, Formal analysis, Methodology, Software. Hong Xu: Project administration. Ming Yang: Resources. Yilan Zeng: Supervision. Hong Chen: Resources. Ru Liu: Qingfeng Li: Resources. Na Zhang: Resources. Dan Wang: Data curation.

Declaration of Competing Interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled, "Epidemiological Characteristics and Clinical Features of 32 Critical and 67 Noncritical Cases of COVID-19 in Chengdu".

Acknowledgments

This work was supported by the staff of Medical Laboratory, Radiology Department, Research Office in Chengdu Public Health Clinical Medical Center, West China Medical University, and Chengdu University of Traditional Chinese Medicine.

References

[1] WHO, WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 on 21 February 2020, (2020) February https://www.who.int/dg/speeches/ detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-on-21-february-2020.
[2] Y.H. Jin, L. Cai, Z.S. Cheng, et al., A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version), Mil. Med. Res. 7 (1) (2020) 4.

[3] J.Y. Li, Z. You, Q. Wang, et al., The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future, Microbes Infect. (2020).

[4] J.T. Wu, K. Leung, G.M. Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study, Lancet (2020).

[5] W. Wang, J. Tang, F. Wei, Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China, J. Med. Virol. 92 (4) (2020) 441–447.

[6] C. Huang, Y. Wang, X. Li, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506.

[7] N. Chen, M. Zhou, X. Dong, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (10223) (2020) 507–513.

[8] L. Kui, Y.Y. Fang, Y. Deng, et al., Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province, Chin Med J (Engl). (2020).

[9] Y. Liu, Y. Yang, C. Zhang, et al., Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci. China Life Sci. (2020).

[10] Notice of novel coronavirus pneumonia prevention and control plan issued by the general office of the national health and Health Committee (5th ed.). http://www.nhc.gov.cn/xcs/zhengcwj/202002/a5d6f78c48c451c87d3a14889b30147.shtml 2020-02-21.

[11] D. Wang, B. Hu, C. Hu, et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA (2020).

[12] J. She, J. Jiang, L. Ye, L. Hu, C. Bai, Y. Song, novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies, Clin. Transl. Med. 9 (1) (2019) 19 2020.